



August 21, 2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Press release on audited Financial Results for quarter and financial ended June 30, 2024**

We are enclosing herewith the Press Release, regarding the audited Financial Results for quarter and year ended June 30, 2024, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.  
Yours faithfully,

For **Procter & Gamble Health Limited**

**Zeal Rupani**  
Company Secretary



## Procter & Gamble Health Announces Fourth Quarter Results and Fiscal Year Results

**Mumbai, 21<sup>st</sup> Aug, 2024:** Procter & Gamble Health Limited today announced its financial results for the quarter and fiscal year ended June 30, 2024. The fourth quarter reported sales was ₹277 crores, down 5% vs. the previous year, owing to changes in the go-to-market model. The company reported a Profit (before exceptional items and tax) of ₹43 Crore for the quarter, down 3% vs a year ago. The exceptional items include impairment charges amounting to ₹20 crores.

For the fiscal year ended June 30, 2024, the company recorded sales of ₹1129 crores, down 6% vs. a year ago. Profit (before exceptional items and tax) for the fiscal year ended June 30, 2024 was ₹ 294 Crores, down 7% vs a year ago.

**Mr. Milind Thatte, Managing Director, P&G Health India**, commented on the performance, stating, *“Our results this quarter reflect the typically seasonality of shipments during this period. In addition, we’ve made choices to strengthen the execution of our integrated strategy with the deployment of a transformed go-to-market model. We’re confident these changes will deliver superior reach, distribution, retail execution and improve our long-term competitiveness. Our strategy remains anchored on a focused product portfolio where performance is a key driver of brand preference, superiority (across product performance, packaging, brand communication, retail execution and value), constructive disruption and an agile, accountable organization. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth and value creation.”*

*“We continue to navigate the evolving market dynamics with resilience and explore innovative solutions to ensure our trusted, quality brands remain the preferred choice for healthcare professionals and consumers alike”,* he added.

*The Board of Directors has recommended a final dividend of ₹60 per Equity Share, for the Financial Year ending June 30, 2024. Considering the interim dividend of ₹200 per share (including the one-time special dividend of ₹150 per share), the total dividend payout for the fiscal will be ₹260 per share, subject to the approval of the final dividend by shareholders of the company at the ensuing 57<sup>th</sup> Annual General Meeting.*

**About Procter & Gamble Health Limited:** Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

**About Procter & Gamble:** P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

### CONTACTS

**Media Contacts - Procter & Gamble Health Limited:**

Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

**Agency Contact – SPAG FINN Partners**

Sarah Rajan | [sarah.rajan@finnpartners.com](mailto:sarah.rajan@finnpartners.com)

Jyotsana Saluja | [Jyotsana.saluja@finnpartners.com](mailto:Jyotsana.saluja@finnpartners.com)